Drug Patents owned by Almirall

1. Drug name - ACZONE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9517219 ALMIRALL Topical dapsone and dapsone/adapalene compositions and methods for use thereof Nov, 2033

(11 years from now)

US9161926 ALMIRALL Topical dapsone and dapsone/adaplene compositions and methods for use thereof Nov, 2033

(11 years from now)

Drugs and Companies using DAPSONE ingredient

Treatment: Topical treatment of acne vulgaris

Dosage: GEL;TOPICAL

More Information on Dosage
Strength Dosage Availability
7.5% GEL;TOPICAL Prescription

2. Drug name - ALTABAX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7875630 ALMIRALL Process salts compositions and use
Feb, 2027

(4 years from now)

EP1663220A4 ALMIRALL Novel Process, Salts, Compositions And Use
Aug, 2024

(1 year, 11 months from now)

EP1663220A1 ALMIRALL Novel Process For The Preparation Of Pleuromutilin Derivatives
Aug, 2024

(1 year, 11 months from now)

EP1663220B1 ALMIRALL Novel Process For The Preparation Of Pleuromutilin Derivatives
Aug, 2024

(1 year, 11 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8207191 ALMIRALL Process, salts, composition and use Aug, 2024

(1 year, 11 months from now)

Drugs and Companies using RETAPAMULIN ingredient

Treatment: Treatment of impetigo due to staphylococcus aureus or streptococcus pyogenes

Dosage: OINTMENT;TOPICAL

More Information on Dosage
Strength Dosage Availability
1% OINTMENT;TOPICAL Prescription

3. Drug name - KLISYRI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8236799 ALMIRALL Biaryl compositions and methods for modulating a kinase cascade
Dec, 2025

(3 years from now)

US8980890 ALMIRALL Compositions and methods of treating cell proliferation disorders
Dec, 2025

(3 years from now)

US7300931 ALMIRALL Compositions for treating cell proliferation disorders
Feb, 2026

(3 years from now)

US7851470 ALMIRALL Composition and methods for modulating a kinase cascade
Feb, 2029

(6 years from now)

US10669236 ALMIRALL Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide
Sep, 2038

(15 years from now)

CN101184734B ALMIRALL Compounds And Methods For Treating Cell Proliferation Disorders
Dec, 2025

(3 years from now)

CN103274961B ALMIRALL Compounds And Methods For Treating Cell Proliferation Disorders
Dec, 2025

(3 years from now)

CN101184734A ALMIRALL Compound And Method For Treating Cell Proliferation Disorders
Dec, 2025

(3 years from now)

CN103274961A ALMIRALL Compounds And Methods For Treating Cell Proliferation Disorders
Dec, 2025

(3 years from now)

CN101595084B ALMIRALL Biaryl Compositions And Methods For Modulating A Kinase Cascade
Jun, 2027

(4 years from now)

CN101595084A ALMIRALL Biaryl Compositions And Methods For Modulating A Kinase Cascade
Jun, 2027

(4 years from now)

CN101616915B ALMIRALL A Method And Composition Of A Kinase Cascade
Dec, 2027

(5 years from now)

CN101616915A ALMIRALL Composition And Methods For Modulating A Kinase Cascade
Dec, 2027

(5 years from now)

CN101687798B ALMIRALL Process For Preparing Modified Kinase Cascade Composition And Using Method Thereof
May, 2028

(5 years from now)

CN101687798A ALMIRALL Process For Preparation Of Compositions For Modulating A Kinase Cascade And Methods Of Use Thereof
May, 2028

(5 years from now)

IN200702504P2 ALMIRALL Compositions And Methods Of Treating Cell Proliferation Disorders
Dec, 2025

(3 years from now)

IN201400549P2 ALMIRALL Compounds For Treating Cell Proliferation Disorders
Dec, 2025

(3 years from now)

IN259746B ALMIRALL Compositions And Methods Of Treating Cell Proliferation Disorders
Dec, 2025

(3 years from now)

IN339823B ALMIRALL Compounds For Treating Cell Proliferation Disorders
Dec, 2025

(3 years from now)

EP1836169B1 ALMIRALL Compositions And Methods Of Treating Cell Proliferation Disorders
Dec, 2025

(3 years from now)

EP1836169A2 ALMIRALL Compositions And Methods Of Treating Cell Proliferation Disorders
Dec, 2025

(3 years from now)

EP1836169B9 ALMIRALL Compositions And Methods Of Treating Cell Proliferation Disorders
Dec, 2025

(3 years from now)

EP2041071B1 ALMIRALL Biaryl Compositions And Methods For Modulating A Kinase Cascade
Jun, 2027

(4 years from now)

EP2041071A2 ALMIRALL Biaryl Compositions And Methods For Modulating A Kinase Cascade
Jun, 2027

(4 years from now)

EP2114934B1 ALMIRALL Composition And Methods For Modulating A Kinase Cascade
Dec, 2027

(5 years from now)

EP2114934A1 ALMIRALL Composition And Methods For Modulating A Kinase Cascade
Dec, 2027

(5 years from now)

EP2155681B1 ALMIRALL Process For The Preparation Of Compositions For Modulating A Kinase Cascade And Methods Of Use Thereof
May, 2028

(5 years from now)

EP2155681A1 ALMIRALL Process For The Preparation Of Compositions For Modulating A Kinase Cascade And Methods Of Use Thereof
May, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10323001 ALMIRALL Compositions for modulating a kinase cascade and methods of use thereof Dec, 2027

(5 years from now)

US10617693 ALMIRALL Methods of treating and/or preventing actinic keratosis Mar, 2038

(15 years from now)

Drugs and Companies using TIRBANIBULIN ingredient

Treatment: Topical treatment of actinic keratosis of the face or scalp

Dosage: OINTMENT;TOPICAL

More Information on Dosage
Strength Dosage Availability
1% OINTMENT;TOPICAL Prescription

4. Drug name - SEYSARA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8318706 ALMIRALL Substituted tetracycline compounds
May, 2031

(8 years from now)

US9255068 ALMIRALL Crystalline salts of (4S,4AS,5AR,12AS)-4-dimethylamino-3,10,12,12A-tetrahydroxy-7-[methoxy(methyl)amino)-methyl] acid amide and methods of using the same
Feb, 2033

(10 years from now)

EP2450347B1 ALMIRALL Tetracycline Derivatives For The Treatment Of Bacterial, Viral And Parasitic Infections
Dec, 2027

(5 years from now)

EP2450347A1 ALMIRALL Tetracycline Derivatives For The Treatment Of Bacterial, Viral And Parasitic Infections
Dec, 2027

(5 years from now)

EP2109602B1 ALMIRALL Tetracycline Derivatives For The Treatment Of Bacterial, Viral And Parasitic Infections
Dec, 2027

(5 years from now)

EP2109602A2 ALMIRALL Tetracycline Derivatives For The Treatment Of Bacterial, Viral And Parasitic Infections
Dec, 2027

(5 years from now)

EP2455367A1 ALMIRALL Tetracycline Derivatives For The Treatment Of Bacterial, Viral And Parasitic Infections
Dec, 2027

(5 years from now)

EP2455367B1 ALMIRALL Tetracycline Derivatives For The Treatment Of Bacterial, Viral And Parasitic Infections
Dec, 2027

(5 years from now)

EP2707003A1 ALMIRALL Crystalline Salts Of (4S,4As,5Ar,12As)-4-Dimethylamino-3,10,12,12A-Tetrahydroxy-7-[(Methoxy(Methyl)Amino)-Methyl]-1,11-Dioxo-1,4,4A,5,5A,6,11,12A-Octahydro-Naphthacene-2-Carboxylic Acid Amide And Methods Of Using The Same
May, 2032

(9 years from now)

EP2707003B1 ALMIRALL Crystalline Salts Of (4S,4As,5Ar,12As)-4-Dimethylamino-3,10,12,12A-Tetrahydroxy-7-[(Methoxy(Methyl)Amino)-Methyl]-1,11-Dioxo-1,4,4A,5,5A,6,11,12A-Octahydro-Naphthacene-2-Carboxylic Acid Amide And Methods Of Using The Same
May, 2032

(9 years from now)

EP2707003A4 ALMIRALL Crystalline Salts Of (4S,4As,5Ar,12As)-4-Dimethylamino-3,10,12,12A-Tetrahydroxy-7-[(Methoxy(Methyl)Amino)-Methyl]-1,11-Dioxo-1,4,4A,5,5A,6,11,12A-Octahydro-Naphthacene-2-Carboxylic Acid Amide And Methods Of Using The Same
May, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9481639 ALMIRALL Substituted tetracycline compounds for treatment of inflammatory skin disorders Aug, 2028

(5 years from now)

US8513223 ALMIRALL Substituted tetracycline compounds for treatment of inflammatory skin disorders Dec, 2029

(7 years from now)

Drugs and Companies using SARECYCLINE HYDROCHLORIDE ingredient

Treatment: A method for treating acne in inflammatory lesions of non-nodular moderate to severe acne vulgaris patients 9 years of age and older comprising administering sarecycline hydrochloride in 60 mg, 100 mg or 150 mg equivalent doses; A method for treating a patient 9 years of age and older suffering from an inflammatory skin disorder of non-nodular moderate to severe acne vulgaris comprising administering an effective amount of sarecycline hydrochloride

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 60MG BASE TABLET;ORAL Prescription
EQ 100MG BASE TABLET;ORAL Prescription
EQ 150MG BASE TABLET;ORAL Prescription

5. Drug name - VERDESO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9492384 ALMIRALL Microemulsion and sub-micron emulsion process and compositions Aug, 2025

(2 years from now)

US8962000 ALMIRALL Microemulsion and sub-micron emulsion process and compositions Aug, 2025

(2 years from now)

US8460641 ALMIRALL Microemulsion process and composition Aug, 2027

(4 years from now)

Drugs and Companies using DESONIDE ingredient

Treatment: Treatment of atopic dermatitis

Dosage: AEROSOL, FOAM;TOPICAL

More Information on Dosage
Strength Dosage Availability
0.05% AEROSOL, FOAM;TOPICAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.